Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | Mar 26, 2024
Distillery Therapeutics
Inhibition for TRPC6 for triple negative breast cancer
BioCentury | Oct 27, 2021
Finance
Bain commits $300M to advance Cardurion’s CV programs
Bain Capital Life Sciences makes first big splash from new $1.9B third fund
BioCentury | Mar 16, 2021
Product Development
March 16 COVID Quick Takes: FDA launches adverse events dashboard; plus Kintor, Boehringer, Apeiron, Moderna and more
FDA launched an FDA Adverse Event Reporting System (FAERS) public dashboard for COVID-19 drugs and biologics with emergency use authorization (EUA). The launch comes as EMA’s Pharmacovigilance
BioCentury | Oct 31, 2020
Product Development
Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida
EMA accepts aducanumab MAA for reviewBiogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) said the EMA accepted for review an MAA for Alzheimer’s disease candidate aducanumab. The
BioCentury | May 21, 2015
Distillery Therapeutics
Therapeutics: Guanine nucleotide binding protein (G protein) q polypeptide (GNAQ; G-ALPHA-q); calcineurin; transient receptor potential cation channel subfamily
Items per page:
1 - 10 of 10